<DOC>
	<DOCNO>NCT01526369</DOCNO>
	<brief_summary>The propose phase III randomise trial compare efficacy trastuzumab paclitaxel trastuzumab , paclitaxel lapatinib first line treatment HER2 positive metastatic breast cancer . The investigator also examine potential predictive biomarkers response trastuzumab lapatinib pre-treatment biopsy sample serum sample .</brief_summary>
	<brief_title>A Randomized Study TH Versus THL First Line Treatment HER2-positive Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>1 . Written inform consent obtain prior studyrelated procedure 2 . Female age 18 year great . 3 . ECOG Performance Status 0 1 . 4 . Histologically cytologicallyconfirmed invasive metastatic breast cancer . 5 . Patients must measurable disease accord RECIST criterion Version 1.1 , define least one lesion accurately measure least one dimension ( long diameter record nonnodal lesion short axis nodal lesion ) &gt; 20 mm conventional technique &gt; 10 mm spiral CT scan , MRI , caliper clinical exam . 6 . Tumour show HER2 overexpression ( 3+ IHC and/or FISH + ) test primary tumour available biopsied metastatic lesion 7 . Patients receive prior radiotherapy must complete least 4 week registration recover treatmentrelated toxicity . 8 . Cardiac ejection fraction within institutional range normal measure MUGA ECHO within 14 day prior registration . Note baseline treatment scan perform use modality preferably institution . 9 . Adequate haematological , hepatic , renal function . Haemoglobin ≥ 9g/dL Neutrophils ( ANC/AGC ) ≥1500/mm³ ( 1.5 x 10^9/L ) Platelets ≥ ( 100 x 10^9/L ) Total bilirubin ≤ 1.5mg/dL ( 25.65 μmol/L ) Both ALT ( SGPT ) AST ( SGOT ) ≤ 3 x ULN without liver Metastasis Alkaline phosphatase ≤ 2.5 x ULN Serum creatinine ≤1.5 ULN calculate creatinine clearance ( CrCl ) ≥ 30mL/min accord Cockcroft Gault formula ( Appendix K ) 10 . Able swallow retain oral medication . 11 . Women childbearing potential must agree use adequate contraception ( hormonal barrier method birth control abstinence ) prior study entry duration study participation . Female patient childbearing potential must pregnancy excluded urine serum betaHCG test within 7 day prior registration . 12 . Estimated life expectancy great 12 week 1 . Prior systemic therapy metastatic disease ( except one line hormonal therapy metastatic disease without trastuzumab ) . 2 . Recurrence within 12 month completion adjuvant chemotherapy development metastatic disease . 3 . Recurrence within 6 month completion adjuvant trastuzumab development metastatic disease . 4 . Prior lapatinib treatment . 5 . Peripheral neuropathy ≥ grade 2 6 . Patients know CNS metastasis exclude clinical trial 7 . Prior radiotherapy half bony pelvis . 8 . Uncontrolled symptomatic angina , uncontrolled arrhythmia , congestive heart failure , document MI within 6 month prior registration cardiac disorder , opinion treat physician , would make protocol unreasonably hazardous patient . 9 . Immediate delay hypersensitivity untoward reaction paclitaxel , trastuzumab , related compound , drug chemically relate lapatinib ( include anilinoquinazolines , e.g . gefitinib ( Iressa® ) erlotinib ( Tarceva® ) , chemicallyrelated compound ) . 10 . Pregnant breastfeed woman exclude study . 11 . Patients receive investigational agent ( within 30 day prior registration ) receive concurrent anticancer therapy . 12 . Concomitant requirement medication classify CYP3A4 inducer inhibitor ( Table 9 ) . 13 . Uncontrolled intercurrent illness include , limited , ongoing active infection , psychiatric illness/social situation would limit compliance study requirement . 14 . Patients GI tract disease result inability take oral medication , malabsorption syndrome , requirement IV alimentation , prior surgical procedure affect absorption , uncontrolled inflammatory GI disease ( e.g. , Crohn 's , ulcerative colitis ) . 15 . Have current active hepatic biliary disease ( exception patient Gilbert 's syndrome , asymptomatic gallstone , liver metastasis stable chronic liver disease per investigator assessment ) 16 . Concurrent treatment ovarian hormone replacement therapy . Prior treatment must stop prior registration .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>HER2-positive metastatic breast cancer .</keyword>
</DOC>